MacroGenics | MGNX - Stock


MacroGenics reported $9.28M in Stock for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 245.42M
Cash and Equivalent USD 130.69M
Cost of Sales USD 49.7M
Current Assets USD 204.94M
Current Liabilities USD 39M
Debt USD 37.25M
EBIT USD -35.34M
EBITDA USD -33.44M
Employees 339
EPS Earnings Per Share USD -0.57
Equity Capital and Reserves USD 46.62M
Gross Profit on Sales USD -27.46M
Interest Expense on Debt USD 802K
Interest Income USD 1.41M
Loan Capital USD 70.26M
Market Capitalization USD 124.9M
Net Income USD -36.25M
Operating Expenses USD 59M
Operating Profit USD -36.76M
Ordinary Share Capital USD 63.21M
Pre-Tax Profit USD -36.15M
Sales Revenues USD 22.24M
Selling and Administration Expenses USD 9.3M
Stock USD 9.28M
Trade Creditors USD 4.66M
Trade Debtors USD 12.53M

Stock Change Date
AbbVie USD 4.53B 345M Mar/2025
Amgen USD 6.58B 146M Jun/2025
AstraZeneca USD 6.47B 583M Jun/2025
Biogen USD 2.27B 400K Jun/2025
Bristol-Myers Squibb USD 2.74B 71M Jun/2025
Daiichi Sankyo JPY 514.91B 39.56B Mar/2025
Eli Lilly USD 11.01B 1.7B Jun/2025
Genmab DKK 13M 1000K Jun/2025
Geron USD 69.12M 12.9M Jun/2025
Gilead Sciences USD 1.83B 66M Jun/2025
J&J USD 12.66B 215M Mar/2025
MacroGenics USD 9.28M 9.28M Jun/2025
Merck USD 6.6B 405M Jun/2025
Pfizer USD 11.67B 817M Jun/2025
Regeneron Pharmaceuticals USD 3.21B 760.7M Jun/2025
Roche Holding CHF 7.61B 339M Dec/2024
Xencor USD 0 0 Jun/2020